ADAP News and Press, Adaptimmune Therapeutics plc From 07/29/19

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 29, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Second Quarter 2019 and provide a business update before the U.S. markets open on Thu...

- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 25, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell thera...

Thinly traded micro cap Adaptimmune Therapeutics plc ( ADAP +10.4% ) is up on modestly higher volume, albeit on turnover of only 306K shares, in reaction to the initiation of a 10-subject radiation sub-study evaluating its ADP-A2M4 SPEAR T cells in patients with solid tumors. More news...

- Compelling responses previously reported with ADP-A2M4 in sarcoma - - Use of low-dose radiation intended to enhance antitumor activity - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cel...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 18, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc, Philadelphia, PA, and Oxfordshire, UK (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated SURPASS, its first clinical trial with a next-generation SPEAR T-cell ...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer (CFO) of the Company, will succeed James Noble as Chief Executive Officer (CEO). This tran...

NetworkNewsWire Editorial Coverage : Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns. Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQ: GNPX) ( GNPX Profile ) is leveraging its patented technology pla...

Adaptimmune ( ADAP +3.7% ) will collaborate with Alpine Immune Sciences ( ALPN +4.4% ) to develop next-generation SPEAR T-cell products based on the latter's secreted and transmembrane immunomodulatory protein (SIP and TIP) technology . More news on: Adaptimmune Therapeutics plc, Al...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle, WA, (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatmen...

Thinly traded micro cap Adaptimmune Therapeutics (NASDAQ: ADAP ) is up  6%  premarket on average volume in reaction to preliminary data in a pilot study of T-cell therapy candidate ADP-A2M4 . More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, Read more ......